A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

A traveller who hopped into his hotel bed only to feel a sudden 'prick' sensation was left panicked after realising what it ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...

The Associated Press Condoms and other sexual wellness items are made available to students at the University of Mississippi ...

1 The phase 3 PURPOSE 2 trial is assessing lenacapavir as a pre-exposure prophylaxis (PrEP) medicine to reduce the chance of getting HIV through sex, comparing it when taken twice per year as PrEP ...

HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP) use in priority populations with unmet needs for PrEP in the U.S. Additional HIV research findings ...

Coverage with biomedical prevention was markedly higher in the dynamic choice group including cabotegravir long-acting injectable (69·7%, 95% CI 64·9–74·5) than with standard of care (13·3%, 10·2–16·3 ...